How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic Authors: Ian C. Murphy, Kelly Bryan, Muriel Burk, Rong Jiang, Francesca Cunningham, Sarah Providence, Elizabeth Rightnour, Sarah Zavala, Kathleen Morneau, Trisha Exline, Stacey Rice, Travis Schmitt, Kelly Drumright, Jennifer Lee, BreAnna Davids, Tram Guilbeault, Brooke Klenosky, Ann-Marie Sutherland, Abbie Rosen, Lauren Ratliff, Kenneth Bukowski, Margaret A. Pisani, Andrew Franck, Mark Wong, Preston Witcher, Kathleen M. Akgün, Benjamin Benzon, Benjamin Benzon, Benjamin Benzon Published: 2025 ABSTRACT OBJECTIVESEarly data suggested higher sedative requirements for ventilated COVID+ patients, deviating from established guidelines. We assessed the relationship between sedative use and outcomes in mechanically ventilated Veterans during the COVID-19 pandemic.DesignRetrospective Medication Use EvaluationSettingNational Sample of 13 Distinct VA Medical Center Intensive Care UnitsPatientsCritically ill Veteran patients requiring mechanically ventilation for ≥2 daysInterventionsNone.Measurements and main resultsThe proportion of patients receiving fentanyl, midazolam and propofol was higher during COVID years. Compared with pre-COVID, median fentanyl dose was higher during Years 1 and 2 (1575mcg [(IQR) 1000–1650] vs. 1900 [1250–3000] vs. 1910 [1150–3500]). Adjuvant antipsychotics use was relatively low but tended to increase over time (pre = 10.5% vs. Year 1 = 12.3% vs. Year 2 = 14.1%). Most patients started on antipsychotics in the ICU were continued on the drug after extubation. Mortality was higher during COVID years (pre = 26.9% vs. 1 = 36.8% and 2 = 35.9%). In stratified analyses by COVID status years 1–2 (n = 79, 27%), a higher proportion of COVID+ patients received fentanyl (96% vs. 84%) and propofol (90% vs. 77%) and at higher doses (fentanyl = 1650mcg vs. 2688mcg median cumulative dose; propofol maximum infusion rate = 30 mc/kg/min (20–50) vs. 40 (25–50)). Sedative doses were similar to pre-COVID among non-COVID patients. Anti-psychotics were more frequently continued post extubation among COVID+ (34.6% vs. non-COVID+=14.9%). COVID+ patients were also less likely to have awakening and breathing trials at 48 hours after intubation (18% vs. 46%).ConclusionsSedative use and dosing increased during the first two years of COVID compared to pre-COVID, especially for COVID+ patients. The sustained elevated levels of fentanyl use in Year 2 suggests possible ‘therapeutic creep’ away from guideline-concordant practices for COVID+ patients. Antipsychotic prescription during intubation and following extubation was also more common among COVID + . These findings could inform development and implementation of safer sedation practices across VA ICUs during respiratory pandemics. Introduction The management of critically ill patients on mechanical ventilation in the intensive care unit (ICU) presents a unique challenge for providers to find a balance between analgesia/anesthesia for ventilator synchrony and wakefulness for early, successful ventilator liberation. Excessive sedative exposure, particularly use of benzodiazepines has been shown to increase time on ventilator, ventilator-associated pneumonia (VAP), delirium risk, ICU, hospital lengths of stay, and patient mortality [1, 2]. Patients who received high doses of sedatives are also at risk for new prescription of antipsychotics while in the ICU [3]. Initiation of these medications is frequently continued beyond ICU stay and often inappropriately at time of discharge [4]. Recognizing the profound impact of sedative choices and practices on patient outcomes, the Pain, Agitation, Delirium, Immobility and Sleep Disruption (PADIS) guidelines have emerged as a pivotal framework for optimizing care and enhancing safety [5]. Addressing these elements comprehensively is imperative, as they are interconnected and contribute synergistically to optimize patient outcomes. Indeed, adherence to PADIS principles is associated with improved patient outcomes by reducing complications such as VAP, length of ICU and hospital stays, and mortality rates [6]. The unprecedented global outbreak for the novel coronavirus (COVID-19) pandemic created a significant challenge to consistent guideline adherence. As the pandemic unfolded, increasing demands were placed on ICUs to manage greater numbers of patients with acute respiratory distress syndrome (ARDS) and mechanically ventilated patients compared with the experiences preceding the COVID-19 pandemic. Early data suggested that ventilated, COVID-infected patients (COVID+) with ARDS required higher than expected doses of sedative medications due to their lung pathology, potentially exceeding current practice standards [7]. While guideline revisions evolve, the broader implications of sedative choices for COVID+ remain unknown. In response, we developed a multi-site Medication Use Evaluation (MUE) quality improvement project to describe the relationship between sedative use and outcomes for mechanically ventilated Veterans. We explored three distinct time points to assess how established sedative and analgesic guidelines were followed. Materials and methods Design A VA-based multi-site MUE was conducted across 13 geographically diverse VA Medical Centers with local champions. Data were accessed and abstracted through retrospective chart review from 01/04/2023–31/08/2023. Patient identifiers were maintained securely within VA systems for review purposes, and all data used for analysis were de-identified or aggregated in accordance with VA policies. We examined data across a 3-year period (March 2019-March 2022), three distinct eras: pre-COVID (March 2019-February 2020), COVID Year 1 (March 2020-February 2021), COVID Year 2 (March 2021-March 2022). This collaborative effort involved clinical pharmacists, intensivists, statisticians and the VA Pharmacy Benefits Management Services Center for Medication Safety (VA MedSAFE). Ethical approval and informed consent The project was reviewed and approved by the Edward Hines VA Hospital IRB Committee as a non-research QI/QA protocol and determined to be a non-research QI/QA protocol. MUE target population All mechanically ventilated patients during each time frame were screened via electronic health record (EHR) review. We included VA ICU patients who received care for ≥1 calendar day and who required mechanical ventilation for ≥2 calendar days. Exclusion criteria were patients who: died or were transferred within 48 hours of admission, were transferred into the ICU from a non-VA facility, were physically located in the ICU but did not receive ICU care, were ventilated for >14 days or those with a pre-existing tracheostomy or pre-existing chronic ventilator use. Data sources and collection At each participating site, data were retrospectively abstracted from chart review conducted between 01/04/2023 and 31/08/2023 and entered into a secure, encrypted InfoPath server hosted within VA systems. A pilot abstraction tool was developed and iteratively refined to identify clinical variables from the EHR. Team members participated in pilot development and were trained on data collection and entry procedures. During review and data entry, site-specific patient lists containing identifiers were maintained within the VA protected environment and accessible only to authorized personnel with proper permissions. Each site reviewed approximately 150–200 patient records. Prior to final analysis, data were screened for irregular or implausible values. Primary outcomes The primary outcome was median dose of sedative and opioid exposure for patients. Medication use was divided into commonly used opioids (fentanyl, hydromorphone, methadone, morphine, oxycodone) and sedatives (dexmedetomidine, diazepam, ketamine, lorazepam, midazolam, and propofol). Opioids were converted to morphine milligram equivalents (MME) doses [8, 9]. Infusion rates were manually collected from clinical information systems used at participating sites and validated through chart review and bar code medication administration (BCMA) data when available. The highest and lowest daily infusion rates were collected per day and extrapolated as a maximum potential exposure and minimum potential exposure per 24 hours of drug infusion. Highest and lowest daily infusion rates were collected per day for each drug. While data on all drugs were collected for the first 14 ICU days, we only presented median rates within the first 48 hours of mechanical ventilation for patients with rate data abstracted due to variability and missingness with longer observation time (Fig 1). Breakdown of Patient Inclusion/ Exclusion and time on ventilator. Use of antipsychotic agents was assessed during ICU stay, overall hospitalization and after discharge. Antipsychotic agents of interest included haloperidol, quetiapine, olanzapine, and aripiprazole. Exposure to antipsychotics was evaluated daily while the patient was intubated and up to three days after extubation, continuation at time out of ICU transfer, at hospital discharge, and at 3 months after discharge. Secondary Outcomes Secondary outcomes included mortality, delirium prevalence, new antipsychotic prescription and ileus, use of reversal agents [10, 11]. Sedation depth was measured using daily Richmond Agitation Sedation Score (RASS) for highest and lowest RASS score/day. Patient data was grouped into categories for daily RASS scoring if at least one reading fell into pre-defined categories (deep = −2 to −5; goal = −1or 0; agitated=+1 to +4). This categorical separation was based on studies evaluating percentage of time at a goal RASS score [12]. Fluctuations were defined if at least two of the RASS categories were identified on the same day. These categories were selected due to known risks of large fluctuations in RASS score during a 24-hour period [13]. We assessed rates of spontaneous breathing trial (SBT) documentation at 24 and 48 hours after intubation. Additional data was collected on rates of spontaneous awakening trials (SAT) or evidence of sedative dose reduction at 24 and 48 hours. Delirium assessment was gathered via documentation of Confusion Assessment Method (CAM-ICU). [14, 15] Patients were evaluated for a documented positive CAM-ICU on each ICU day or if the information was not available. Delirium ascertainment continued up until three days after extubation. Patient comfort was assessed via daily collection of Critical Pain Observation Tool (CPOT) [16] or Numeric Rating Scale (NRS) [17]. The highest and lowest values per day were collected for entirety of ICU stay (up to 14 days) and up to three days after extubation. Patients were followed until death or up until three days after ICU transfer as data was available. Additional analysis was performed to assess differences between COVID+ and non-COVID+ patients during Years 1 and 2 in and primary and secondary outcomes. Covariates Baseline data included ICU admission age, gender, weight (kg) at time of admission, race, ethnicity, comorbid medical conditions (using Charlson comorbidity index (CCI) score) [18, 19] primary location of care (MICU, CCU, SICU, or other location) and COVID+ status and COVID- ARDS. Covariates for processes of care included ventilator settings, vasopressor use, SAT, SBT, need for reintubation, use of restraints, and post-ICU disposition, use of specific reversal agents (methylnaltrexone, flumazenil, and sugammadex use). Statistical analysis Descriptive statistics were used to assess baseline patient characteristics. Data on a continuous scale were presented as median (± interquartile range) while data on a categorical scale was presented as frequencies or percentages. We chose the median value for sedative infusion rates due to available data in CPRS and clinical information systems which include documentation of rate, which is not normally distributed, rather than total dose. Based on available information [20, 21], we estimated that there would be a 30% increase in the median amount of sedative drug received by all patients during the COVID-19 pandemic. To achieve appropriate power to detect this clinically meaningful difference, we estimated that 200 patients should be included in each time period. Following data eligibility screening, we met 72% of our expected sample size. Secondary exploratory analyses compared sedative and opioid exposure by COVID+ status although statistical testing for differences by patient groups was beyond the scope of the MUE quality improvement structure. Results Among 870 patients across the three time periods, 431 (49.5%) with complete data during the first 48 hours were included for chart review; pre-COVID n = 134, Year 1 n = 155, Year 2 = 142 (Fig 1). Demographic characteristics were not significantly different across the time periods (Table 1) with median age = 69, 71, 71, proportion male = 96%, 97%, 95% and identified as white race = 69%, 71%, 70%, respectively. Median CCI was highest pre-COVID = 5.3 vs. Year 1 = 4.7 and Year 2 = 4.0. The medical ICU was the primary service for most patients (78%, 83%, 70% respectively). Mortality was higher during COVID periods vs. pre-COVID (27% vs. Year 1 = 37%, Year 2 = 36%). 10.1371/journal.pone.0340225.t001Table 1Demographic Information for Patient Cohorts by COVID year.VariablePre COVID(n = 134)Year 1(n = 155)Year 2(n = 142)Age Median (IQR)69 (62, 74)71 (63,75)71 (64,76)Male Sex, N (%)129 (96.2)150 (96.7)135 (95.0)Race, N (%) Am. Indian0 (0)0 (0)1 (0.7) Asian000 Black34 (25.3)43 (27.7)34 (24) Hispanic4 (2.9)2 (1.2)4 (2.8) White92 (68.6)110 (71)100 (70.4)Charlson Comorbidities Median (IQR)5.3 (2, 7)4.7 (2, 6)4.0 (2, 5)COVID + , n (%)0 (0)42 (27.1)37 (26.1)Care in MICU, n (%)104 (77.6)128 (82.5)100 (70.4)Discharge Disposition, n (%) Skilled Nursing Facility1 (0.7)2 (1.2)1 (0.7) Inpatient Rehabilitation3 (2.2)–4 (2.8) Step-down ICU33 (24.6)32 (20.6)26 (18.3) Traditional medical floor unit52 (38.8)56 (36.1)49 (34.5) Different ICU (SICU/CCU)1 (0.7)–– Home6 (4.4)6 (3.8)11 (7.7)Mortality n (%)36 (26.9)57 (36.8)53 (35.9) Demographic Information for Patient Cohorts by COVID year. Fentanyl was the most frequently used opioid; median 48-hour dose increased from pre to COVID years (Table 2). Pre-COVID patients (n = 82/109 (75%) with rate data) received a median fentanyl dose of 1575mcg (1000, 2650) vs. Year 1 = 1900 (1250, 3000) and Year 2 = 1910 (1150, 3500); doses varied with COVID+ status during years 1 and 2: COVID+=2605–3000 vs. non-COVID = 1575–1675 (Table 3). Median maximum propofol infusion rate at 24 and 48 hours was similar across the three time periods, but the percentage of patients still receiving propofol after 48 hours increased over time (62%, 66%, 73%, respectively). A similar trend was seen in median maximum midazolam infusion rate with no difference among groups by year (Table 2) but higher midazolam by COVID+ status. Additionally, a significantly higher portion of patients were treated with a midazolam infusion after 48 hours (10%, 18%, 16%, respectively). In contrast, dexmedetomidine use decreased from pre- vs. COVID years and appeared to be used differently in Year 1 vs. Year 2 by COVID status. There was minimal use of reversal agents across time periods. The percentage of patients diagnosed with ileus was also low and similar across time periods, 5.2% in pre-COVID, 7.1% in Year 1 and 6.3% in Year 2. 10.1371/journal.pone.0340225.t002Table 2Sedative and Fentanyl Exposure in Mechanically Ventilated Veterans during the first 48 Hours after Intubation.ParameterPre COVID(n = 134)Year 1Overall (n = 155)Year 2Overall (n = 142) Fentanyl, n (%)109 (81)132 (85)125 (88) Fentanyl, Median Total Dose, mcg (IQR)*1575 (1000, 2650)1900 (1250, 3000)1910 (1150, 3500) Midazolam, n (%)36 (27)46 (30)46 (32) Midazolam, Median Max rate, mg/hr (IQR)*4 (2.0, 4.0)4 (2.5, 9.0)3.5 (2.0, 6.0) Dexmedetomidine, n (%)67 (50)66 (43)61 (43) Dexmedetomidine, Max rate, mcg/kg/hr (IQR)*0.7 (0.4, 1.0)0.65 (0.4, 0.9)0.6 (0.5, 1.0) Propofol, n (%)99 (74)121 (78)118 (83) Propofol, Med Max rate, mcg/kg/min (IQR)*33 (20, 50)30 (20,45)35 (20, 50) Neuromuscular blocker, n (%)5 (3.7)27 (17.4)25 (17.6) Processes of ventilator care on intubation day 2 Spontaneous Awakening Trial or Sedative Dose Reduction, n (%)69 (53.4)55 (36.8)56 (40.1) Spontaneous Breathing Trial, n (%)33 (25.5)33 (22.1)34 (24.4) Pts w/ Ileus, n (%)7 (5.2)11 (7.1)9 (6.3)*Rate data available for subset of patients receiving sedative medication, representing:Pre COVID: fentanyl=82/109 (75%), midazolam=14/36 (39%), dexmedetomidine=40/67 (60%), propofol=83/99 (84%)).Year 1: fentanyl=108/132 (82%), midazolam=28/46 (61%), dexmedetomidine=34/66 (52%), propofol=102/121 (84%)).Year 2: fentanyl=99/125 (79%), midazolam=23/46 (50%), dexmedetomidine=31/61 (51%), propofol=103/118 (87%)). Sedative and Fentanyl Exposure in Mechanically Ventilated Veterans during the first 48 Hours after Intubation. *Rate data available for subset of patients receiving sedative medication, representing: Pre COVID: fentanyl=82/109 (75%), midazolam=14/36 (39%), dexmedetomidine=40/67 (60%), propofol=83/99 (84%)). Year 1: fentanyl=108/132 (82%), midazolam=28/46 (61%), dexmedetomidine=34/66 (52%), propofol=102/121 (84%)). Year 2: fentanyl=99/125 (79%), midazolam=23/46 (50%), dexmedetomidine=31/61 (51%), propofol=103/118 (87%)). 10.1371/journal.pone.0340225.t003Table 3COVID vs. Non-COVID Group Stratification during Years 1 and 2.OverallYear 1Year 2COVID+(n = 79)Non COVID(n = 218)COVID+(n = 42)Non COVID(n = 113)COVID+(n = 37)Non COVID(n = 105) Fentanyl74 (96)183 (84)38 (90)94 (83)36 (97)89 (85) Fentanyl, Median Total Dose, mcg (IQR)*2688(1722.5, 4025)1650(1080, 2800)2605(1840, 3820)1675(1080, 3000)3000(1658, 4700)1575(1050, 2575) Midazolam, n (%)30 (38)62 (28)13 (31)33 (29)17 (46)29 (28) Dexmedetomidine, n (%)34 (43)93 (43)21 (50)45 (40)13 (35)48 (46) Propofol, n (%)71 (90)168 (77)35 (83)86 (76)36 (97)82 (78) Propofol, Med Max rate, mcg/kg/min (IQR)*40 (25-50)30 (20-50)37 (18, 50)30 (20, 45)45 (30, 50)30 (20, 50) Neuromuscular blocker, n (%)38 (48)14 (6)16 (38)11 (10)22 (59)3 (3) Processes of ventilator care on intubation day 2 and outcomes SAT or Sedative Dose Reduction, n (%)14 (18)97 (46)7 (5)48 (33)7 (5)49 (35) Spontaneous Breathing Trial, n (%)7 (9)60 (28)5 (3)28 (19)2 (1)32 (23) Ileus, n (%)3 (4)17 (8)1 (2)10 (9)2 (5)7 (6)IQR=interquartile range; SAT=Spontaneous awakening trialYear 1: fentanyl=108/132 (82%), midazolam=28/46 (61%), dexmedetomidine=34/66 (52%), propofol=102/121 (84%)).Year 2: fentanyl=99/125 (79%), midazolam=23/46 (50%), dexmedetomidine=31/61 (51%), propofol=103/118 (87%)). COVID vs. Non-COVID Group Stratification during Years 1 and 2. IQR=interquartile range; SAT=Spontaneous awakening trial Year 1: fentanyl=108/132 (82%), midazolam=28/46 (61%), dexmedetomidine=34/66 (52%), propofol=102/121 (84%)). Year 2: fentanyl=99/125 (79%), midazolam=23/46 (50%), dexmedetomidine=31/61 (51%), propofol=103/118 (87%)). Median number of ventilator days with ≥1 RASS assessment was 4 (3,7). Pre-COVID patients had the highest percentage of days with a RASS score at goal (79.8%); COVID Year 2 patients also had 78.8% of days with goal RASS. In contrast, Year 1 had a lower percentage of patients with a goal RASS (66.4%). Across all time periods a total of 33.2% of patients had at least one day with a positive CAM-ICU score. Similar to RASS fluctuation data, there was an increased number of median CAM-ICU+ days for the COVID Year 1 cohort = 5 days (4,8), compared to pre-COVID and COVID Year 2 which each had a median of 4 days. Differences in rates of documented SAT and SBT data also emerged in comparison by time period. A higher percentage of pre-COVID patients had a documented SAT or reduction in sedative dose on Day 2 of intubation (53.4%) compared to Year 1 (36.8%) and Year 2 (40.1%). Rates of SBT at Day 2 of intubation were more consistent across the 3 cohorts (25.5%, 22.1%, and 24.4%, respectively). Within the entire cohort, a total of 12.3% of patients received an antipsychotic medication, most commonly quetiapine (43%) and haloperidol (30%). Although antipsychotic use was relatively low, it tended to increase from pre-COVID to Year 2 (pre = 10% vs. Year 1 = 12% vs. Year 2 = 14%) (Table 4). Most patients started on antipsychotics in the ICU were continued on the drug at time of transfer out of the ICU, 12/14 (85%) patients pre-COVID, 17/19 (89%) in Year 1 and 20/20 (100%) in Year 2, and 20–30% were continued at hospital discharge in each time period. By 3 months post discharge, all newly prescribed antipsychotics were discontinued. 10.1371/journal.pone.0340225.t004Table 4Delirium and Antipsychotic Use During and Post-ICU Discharge for Mechanically Ventilated Patients Across 3 Time Periods.ParameterPre COVID(n = 134)Year 1(n = 155)Year 2(n = 142)Intubated CAM-ICU+ Days Median (IQR)4 (3, 7)5 (4, 8)4 (3, 7)Extubated CAM-ICU+ Days Median (IQR)1 (1, 2)2 (1, 3)1 (1, 3)Prescribed an Antipsychotic in the ICU, n (%)14 (10.5)19 (12.3)20 (14.1)Antipsychotic continued post-ICU, n (%)12 (9.0)17 (11.0)20 (14.1)Antipsychotic continued at discharge n (%)4 (3.0)5 (3.2)3 (2.1) Delirium and Antipsychotic Use During and Post-ICU Discharge for Mechanically Ventilated Patients Across 3 Time Periods. When stratified by COVID + , COVID+ patients’ median age in years was 72 vs. 70 and median CCI was lower (3.6) vs. non-COVID+ (4.6); ARDS was identified in 78% of COVID+ compared with 4% of uninfected. Secondary analysis demonstrated higher drug exposure for COVID+ (Table 3). During COVID years and compared with non-COVID patients, a higher proportion of COVID+ received fentanyl (84% vs. 96%) and propofol (77% vs. 90%) at any time during the first 14 ICU days (Table 3). COVID+ also received higher doses of fentanyl (median dose = 1650mcg vs. 2688 mcg), midazolam (Year 1 median dose COVID+=7 [interquartile range 3, 10] vs. 4 [2, 8]; Year 2 COVID+=5 [2, 6] vs. 3 [3, 4]) and propofol (median max 48-hr infusion rate = 30 mcg/kg/min (20–50) vs. 40 mcg/kg/min (25–50)) during the same time period. Dexmedetomidine doses were similar between the two groups (Year 1 median dose COVID+=0.6 [0.4, 0.8] vs. 0.7 [0.3, 1.0]; Year 2 COVID+=0.5 [0.5, 0.5] vs. 0.7 [0.5, 1.0]). Anti-psychotics were more frequently continued among COVID+ patients post extubation vs. non-COVID (34.6% vs. 14.9%). In contrast to the higher rates of sedation, COVID+ patients had lower rates of SATs and SBTs at 48 hours post intubation. Only 18% of COVID+ patients had a documented SAT or sedative dose reduction compared to 45.8% of non-COVID patients. A similar trend was found in SBT percentages with 9.2% of COVID+ patients having documentation of a breathing trial compared to 28.2% of non-COVID patients. Mortality was higher in COVID+ patients, 71% compared to non-COVID patients 24%, across the time periods of interest. Discussion This MUE demonstrates shifts in sedation practices within the VA healthcare system during the initial two years of the COVID-19 pandemic, indicating an increase in sedation use and dosing compared to the pre-COVID era. When stratified by COVID status, the increased sedative use was for patients with COVID compared with the non-COVID patients. Anecdotally, higher sedation was likely needed to support patients on the ventilator although we were unable to report ARDS severity in this work. Staffing ratios appeared to be relatively stable, although this was not specifically measured. Our data also illustrate that these shifts were occurring across a nationally representative sample of patients in the VA. Our findings align with observations from smaller, non-VA studies suggesting a general trend towards increasing sedative use due to the unique challenges posed by COVID-19 in critical care settings [7, 20, 22]. Similar to one single-center study including 86 COVID + , more than 50% of COVID+ received sedative doses that exceeded the upper limit of hospital guidelines [21]. Evaluating consequences of deviations from sedation guidelines is ongoing. A large retrospective cohort study demonstrated an association between higher doses of sedatives given to COVID+ patients and increased mortality [20]. Multiple potential reasons for sedation escalation have been proposed. The need to achieve ventilator synchrony in the setting of exaggerated inflammatory response and complex respiratory mechanics from COVID+ ARDS likely contributed to higher sedation [23]. Moreover, COVID+ ARDS compared to age-matched controls required higher doses of sedatives, oftentimes more benzodiazepines to achieve the same level of sedation [24]. Factors more extrinsic to the COVID-19 pandemic like staffing pressures, lack of adequate personal protective equipment (PPE), medication shortages, provider fatigue and incomplete understanding of the disease process also could have significantly impacted sedation practices [25]. The escalated use of sedatives, particularly midazolam, underscores the deviation from guideline-driven management strategies for ventilated COVID+ patients. While benzodiazepines were originally part of first line sedation, growing literature has demonstrated increased patient harms with use, and thus advocating for minimal midazolam exposure for sedated patients [26]. While these changes may reflect a potential adaptation to the heightened requirements for mechanical ventilation, they potentially contributed to poorer patient outcomes. Recent studies demonstrated increased mortality for COVID+ patients in hospitals that used primarily opioids and benzodiazepines compared to those using propofol and opioids for sedation [27, 28]. We noted an increased percentage of patients exposed to midazolam in COVID Years 1 and 2 compared to pre-COVID, although this was more frequently occurring for patients with COVID and appeared to be returning to pre-COVID practices for patients without COVID by Year 2. We expected to observe higher mortality during COVID Year 1, compared to pre-COVID given the overwhelming nature of initial COVID surges. However, we noted unexpected sustained increased mortality in Year 2, despite a lower median CCI score and an assumption that providers had become more adept at managing COVID ARDS. While multiple explanations of this sustained worsened mortality exist, we speculate that the ongoing increased sedative, particularly benzodiazepine use, may have played a role in negatively affecting patient outcomes. We propose that returning to sedation stewardship principles could improve ICU care for patients on the ventilator. Our data also indicate a trend toward disparate use of antipsychotic medications during the first two years of the COVID-19 pandemic. During all time periods, antipsychotics started in the ICU were rarely discontinued at time of transfer. Of note, antipsychotic prescription during intubation and following extubation were more commonly seen among COVID+ patients. The pandemic’s onset marked a noticeable increase in the incidence of delirium among ICU patients, particularly those exposed to benzodiazepines [29]. Moreover, COVID+ correlated with a reduced rate of spontaneous awakening and breathing trials, critical components in the pathway towards extubation, sedation liberation and ICU discharge. Higher rates of delirium may have led to increased antipsychotic prescription, and lack of clear safeguards prevented appropriate medication reconciliation at time of transfer. This relationship underscores the complex interplay between sedative management, patient condition, and the resultant neuropsychiatric outcomes, highlighting the nuanced challenges faced in the pharmacological care of COVID-19 patients. The persistent high utilization of fentanyl and midazolam into the second year of the pandemic hints at a phenomenon of ‘therapeutic creep,’ where there is a gradual and sustained shift in clinical practice away from existing guideline-concordant sedation strategies. This phenomenon is not well described in the literature but is certainly felt within the medical community [30]. In cases of “sedation creep”, providers become comfortable with higher doses or duration of medications and continue those practices, even beyond the stressors of a pandemic surge. However, we only characterize sedative use during the first two years of the COVID pandemic and do not have “post-pandemic” practices to evaluate whether sedation creep is occurring. We also are unable to characterize ARDS severity or prone positioning, which would also influence sedation needs. Ongoing efforts are needed to promote guideline-concordant ICU sedation practices for patients on the ventilator. Several important limitations were identified with this MUE quality improvement project. First, we restricted data analysis to sedation and opioid use during the initial 48 hours of mechanical ventilation; we were unable to get hour-by-hour infusion rates, potentially overlooking changes in medication regimens even during that timeframe that could impact patient outcomes. We also only had complete data for the first 48 hours of all included patients due to the rapid decrease in ventilator use subsequently (Fig 1), limiting our ability to comprehensively evaluate ICU medication use. Additionally, this was a retrospective chart review methodology, limiting our data to what was documented in the EHR. Furthermore, the findings from the MUE are meant to inform Veteran care in the ICU rather than evaluating for statistically significant differences in groups included in this project; our findings are also potentially not generalizable to non-VA settings. Moreover, the rate of exclusion stemming from mechanical ventilation durations less than 2 days or exceeding 14 days may introduce selection bias, potentially skewing the representativeness of the cohort and limiting the extrapolation of results to patients with prolonged ventilation requirements. Finally, our findings are only descriptive frequencies and do not include patient-centered outcomes to better understand how medication use impacted clinical experiences for patients with ARDS. Conclusion Our MUE findings advocate for sedation guideline realignment for ventilated patients and de-prescribing strategies upon transfer out of the ICU to minimize the unnecessary continuation of neuropsychiatric medications. The insights gained from this comprehensive analysis not only shed light on the evolving sedation practices because of the COVID-19 pandemic but also serve as a valuable foundation for the development and implementation of safer, evidence-based sedation guidelines across VA ICUs. Moving forward, it is imperative to integrate these lessons into clinical protocols to enhance patient outcomes and align practices with the latest clinical evidence and standards in VA ICUs. 28 Nov 2025 PONE-D-25-50605-->-->How Much is Too Much? A Medication Use Evaluation of VA ICU Sedation Practice During the COVID-19 Pandemic-->?> PLOS ONE Dear Dr. Akgün, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Thank you for sending your manuscript to PLOS One. Reviewers are two anesthesiologists with extensive experience in COVID ICU, please address their comments. I am looking forward to revised version of the manuscript. ============================== Please submit your revised manuscript by Jan 12 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Benjamin Benzon, Ph.D., M.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf . 2. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.x Please update your Data Availability statement in the submission form accordingly. 3. Please be informed that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Although study is interesting, there are some problems with methodology and interpretation od data. This retrospective study limitation is just collecting data for 48 h sedation. It is not clear for me how this narrow time periods support your conclusion. This study is not patient centred. You did not reach estimated sample size. COVID ARSD was unique lung patology, the worst cases that would dye spontaneously breading was put on mechanical ventilation, and stiff lungs were hard to ventilate. It was necessary to give more sedation than non COVID ICU patients to achieve smooth ventilation, maybe muscle relaxation was under dosed and sedation overdosed, but still it is not clear to me was you can infer for just 2 days of ICU sedation. In the first 2 days it is hard to have prognosis (survival or death). I think conclusion is not supported by data and study design. Reviewer #2: I would like to see your opinions in discussion section what were the possible reasons for analgosedation increase in Covid patients? Was it too many difficult patients and too little doctors and nurses so they could not take care as usual? Did you calculate Horowitz index for ARDS severity? What was vaccination status in year 2? Did you put patients in prone position for better ventilation? All above are possible factors for analgosedation increase. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 9 Dec 2025 please see attached response letter for improved formatting Reviewer: 1 Comments to the Author Although study is interesting, there are some problems with methodology and interpretation od data. Reviewer comment 1: This retrospective study limitation is just collecting data for 48 h sedation. Reply 1: We agree that this is a limitation. However, complete data was only available during the first 48 hours; by day 5, more than half of the patients were off of the ventilator. We included these details in figure 1 and in the text, and as additional limitations in the manuscript. Results, page 10, lines 294-295: “431 (49.5%) with complete data during the first 48 hours were included for chart review” Discussion, page 16, lines 408-410: “We also only had complete data for the first 48 hours of all included patients due to the rapid decrease in ventilator use subsequently (Figure 1), limiting our ability to comprehensively evaluate ICU medication use.” Additional table added to figure 1: Patients on ventilator by day, up to 14 days, N (%) Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 N (%) 431 (100) 431 (100) 390 (90) 291 (68) 204 (47) 156 (36) 118 (27) 91 (21) 72 (17) 53 (12) 34 (8) 20 (5) 15 (3) 7 (2) Reviewer comment 2: It is not clear for me how this narrow time periods support your conclusion. Reply 2: We merely intended to report observations of medication prescribing in a national sample. We feel our conclusions are tempered and seeking to remind providers of the importance of sedation protocols and sedation stewardship. Reviewer comment 3: This study is not patient centred. Reply 3: As a chart review study, we agree we are limited in patient-centered outcomes. We included this as another limitation in the manuscript. Discussion, page 17, lines 439-441: “Finally, our findings are only descriptive frequencies and do not include patient-centered outcomes to better understand how medication use impacted clinical experiences for patients with ARDS.” Reviewer comment 4: You did not reach estimated sample size. Reply 4: We regret that we did not reach our intended goals for chart review due to exclusion criteria. This was included as a limitation already in the manuscript. Reviewer comment 5: COVID ARSD was unique lung patology, the worst cases that would dye spontaneously breading was put on mechanical ventilation, and stiff lungs were hard to ventilate. It was necessary to give more sedation than non COVID ICU patients to achieve smooth ventilation, maybe muscle relaxation was under dosed and sedation overdosed, but still it is not clear to me was you can infer for just 2 days of ICU sedation. In the first 2 days it is hard to have prognosis (survival or death). I think conclusion is not supported by data and study design. Reply 5: Please see response to comments 1 and 2 above. We also included more context about the stiff lung physiology of COVD ARDS. Discussion, page 13, lines 372-374: “The need to achieve ventilator synchrony in the setting of exaggerated inflammatory response and complex respiratory mechanics from COVID+ ARDS likely contributed to higher sedation.” Reviewer: 2 Reviewer comment 1: I would like to see your opinions in discussion section what were the possible reasons for analgosedation increase in Covid patients? Was it too many difficult patients and too little doctors and nurses so they could not take care as usual? Reply 1: We speculated about some of these factors that contributed to higher analgosedation for COVID patients, including possible staffing shortages, but more granular assessments of staffing models. Discussion, page 13, lines 360-363: “Anecdotally, higher sedation was likely needed to support patients on the ventilator although we were unable to report ARDS severity in this work. Staffing ratios appeared to be relatively stable, although this was not specifically measured.” Reviewer comment 2: Did you calculate Horowitz index for ARDS severity? What was vaccination status in year 2? Did you put patients in prone position for better ventilation? All above are possible factors for analgosedation increase. Reply 2: We did not calculate the Horowitz index for ARDS severity. We also were unable to include information on vaccination status or prone positioning. We included these as additional limitations. Discussion, page 16, lines 421-423: “We also are unable to characterize ARDS severity or prone positioning, which would also influence sedation needs. Ongoing efforts are needed to promote guideline-concordant ICU sedation practices for patients on the ventilator.” 18 Dec 2025 How Much is Too Much? A Medication Use Evaluation of VA ICU Sedation Practice During the COVID-19 Pandemic PONE-D-25-50605R1 Dear Dr. Akgün, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Benjamin Benzon, Ph.D., M.D. Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-50605R1 PLOS One Dear Dr. Akgün, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Benjamin Benzon Academic Editor PLOS One